#CAR-T Therapy for #MS. New MS Living Well podcast with @JeffreyDunnMD & Amanda Piquet MD. https://t.co/aLxFwOouCF 🍎 https://t.co/fgc2ou4Vrf @hwiendl @KlausSchmierer @C_OrejaGuevara @J_SastreGarriga @Pluchinolab @MStranslate Sponsor: @TGTherapeutics

Early exciting results! 🌞 #CAR-T Therapy for #MS. New MS Living Well podcast! Pop on your🎧 https://t.co/aLxFwOp2sd 🍎 https://t.co/fgc2ou5tgN @Brandon_Beaber @MSViewsandNews @MustStopMS @DrJNicholas @DocforMS @anneke_vdw @RumaizaAlyafeai

Teslas have the lowest maintenance & repair costs of any brand

CCMR trial pretty disappointing effect of the combination of clemastine and metformin compared to placebo for #remyelination in #MS. Statistically positive result on visual evoked potentials, but clinically insignificant 1.2 msec difference. #ECTRIMS2025

OPERETTA 2 trial: Phase 3 #pediatric #MS #POMS study. #Ocrelizumab associated with 48% reduction in both annualized relapses and new or enlarging T2 lesions, compared to fingolimod, a FDA-approved treatment for multiple sclerosis. #ECTRIMS2025

ORATORIO-HAND trial: #Ocrelizumab reduced progression composite by 30%. 48% reduction (24-week confirmed) in worsening on 9-hole peg test of hand function. #MS patients in wheelchairs 👩‍🦽‍➡️had benefit on preserving hand function. 👏 #ECTRIMS2025

#Frexalimab treatment resulted in a sustained reduction of disease activity over 2.5 years, demonstrated by a low number of Gd+ T1 lesions and new/enlarging T2 lesions. No impact on lymphocyte counts and immunoglobulin levels. #ECTRIMS2025

Ramanathan: #MOGAD maintenance treatments currently used include IVIG, rituximab and tocilizumab without phase 3 trial supportive data. New treatments in development; see below 👇 #ECTRIMS2025

Wiendl: #BTK inhibitors moving forward in clinical trial programs to treat #MS. Dates of study readouts shared and clinical scenarios where BTK inhibitors might be used shared. #ECTRIMS2025

Salvetti: Epstein-Barr virus #EBV vaccination development may be key to preventing #MS. Challenging since the process of EBV infecting B cells or epithelial cells significantly differs but partially overlaps. Is sterilizing immunity necessary? #ECTRIMS2025

Thanks, @ECTRIMS, for the opportunity to share some insights from a meaningful Day 2 at #ECTRIMS2025 on the #ECTRIMS podcast 🎧. Covered environmental triggers, remyelination and more!

Wooliscroft: Moderate to vigorous intensity aerobic exercise (70 - 80% HRmax) was associated with improvement in T,-based Myelin Water Fraction (MWF) over a 24-week period. Upshot? Exercise 🚴‍♂️ enhances #remyelination! #ECTRIMS2025

Good morning 🌞 to the #MS community at #ECTRIMS2025! Interested in sharing the latest #MS innovations and tips with your multiple sclerosis patients? 💡👉MS Living Well podcast 🎧 100 interviews with leading global MS experts and patient advocates!

Dalla Costa: #MS patients with highest ultra-processed food #UPF intake quartile experienced about 30% more relapses over five years compared to those with the lowest intake. High #UPF intake? More active MRI lesions. #DietMatters #ECTRIMS2025

Kultima: PFOS & OH-PCBs “forever chemicals” exposure substantially increases risk of multiple sclerosis. A concerning finding. #ECTRIMS2025

Presented ENHANCE trial results at #ECTRIMS2025 Of patients switching from ocrelizumab to #ublituximab, 26% of patients had >=10 cells/μL at baseline (median 9 months since last infusion). Repopulation factors? Black patients, younger age, high BMI. https://t.co/PsXXTVMDcI

Cree: 6-year phase 3 results: ublituximab treatment associated with very low relapse rate (0.012 at year 6) with significant benefit on 24-week confirmed-disability worsening and confirmed disability improvement. #ECTRIMS2025

Roos: Ocrelizumab provides superior control of relapses and RAW compared to fingolimod, and marginally superior control compared to natalizumab and alemtuzumab, especially in patients who previously experienced on-treatment disease activity based on @MSBase_Registry #ECTRIMS2025

How do we slow aging in people with #MS? Graves at #ECTRIMS2025: Don't wait until aged to prevent aging! Build reserve. Measure biological age. Exercise! Mediterranean diet. Treat hypertension and diabetes. Senotherapeutics!

Kerbrat: MS patients age >50 that discontinued or continued B-cell depleting medications have similar outcomes in terms of relapses based on French registry data. #ECTRIMS2024

Amato: Different patterns (phenotypes) of cognitive impairment in MS. 19% preserved cognition, 30% mild verbal memory/semantic fluency, 14% severe attention/executive. Cognitive rehab can induce neuroplasticity. Shifting from Reaction to Prevention is key! Save 🧠!!#ECTRIMS2025